Positive data from two trials in immunoglobulin A nephropathy (IgAN) were shared at the American Society of Nephrology Kidney Week 2024 in San Diego, California.

Vera Therapeutics announced data from its ORIGIN Phase IIb trial of atacicept that showed stabilised kidney function through 96 weeks of long-term follow-up.

Over 96 weeks, participants treated with atacicept demonstrated a -66% reduction in galactose-deficient IgA1 (Gd-IgA1), resolution of haematuria in 75% of participants, a -52% reduction in proteinuria, and a mean annualised estimated glomerular filtration rate (eGFR) slope of -0.6 mL/min/1.73m2/year.

Jonathan Barratt, Mayer Professor of Renal Medicine at the University of Leicester, commented: “Converting patients with IgAN from an eGFR profile of unrelenting decline to a profile consistent with the general population without kidney disease is a differentiated and compelling finding. Collectively, the data support the potential of atacicept to modify the natural history of the disease and prevent kidney failure during the lifetime of patients with IgAN.”

Atacicept is an investigational recombinant fusion protein that contains the soluble transmembrane activator and calcium-modulating cyclophilin ligand interactor receptor that binds to the cytokines B-cell activating factor (BAFF) and A PRoliferation-Inducing Ligand (APRIL).

These cytokines are members of the tumour necrosis factor family that promote B-cell survival and autoantibody production associated with certain autoimmune diseases, including IgAN and lupus nephritis.

""
Figure 1: ORIGIN Phase IIb long-term 96-week results with atacicept was consistent with disease-modifying IgAN profile.
Rapid and sustained reductions in serum IgA

Phase Ib data were also presented on Takeda’s mezagitamab, a fully human anti-CD38 IgG1 monoclonal antibody, which depletes plasma cells, plasmablasts, and natural killer cells expressing CD38.

Mezagitamab depletes cells that produce galactose-deficient IgA1 (Gd-IgA1) and autoantibodies, which results in decreased immune complex formation, potentially reducing proteinuria/promoting stabilisation of kidney function over time.

The treatment was generally well tolerated as an add-on to standard of care therapy.

The data show rapid and sustained reductions from baseline levels in serum IgA (nadir −70.1%) and Gd-IgA1 (nadir −62.2%). At Week 36, a 54.9% mean reduction in proteinuria (UPCR) was observed. Renal function (eGFR) remained stable though Week 36.

Diana Spencer, Senior Digital Content Editor, DDW